![Revolutionary CAR-T therapy aims to expand beyond treating blood cancer | Health 3 M5RS6S6NEBFYNFWO7IBRIUAUDU](https://images.english.elpais.com/resizer/4Rrf8Ne3OGTkB_6r6oSmNe8jU8I=/arc-anglerfish-eu-central-1-prod-prisa/public/M5RS6S6NEBFYNFWO7IBRIUAUDU.jpg)
In just a decade, CAR-T cell therapy has transformed the outlook for individuals with blood cancer by genetically modifying T-lymphocytes to enhance their ability to combat tumors. While the therapy has been effective in treating hematological cancers, its success in solid tumors has been limited. A recent study in Science Advances showcased a new and more potent version of CAR-T, called TOP CAR, which targets the B7-H3 antigen found on tumor cells. This redesigned CAR-T, created by Dr. Xingxing Zang, has shown promising results in animal studies, with improved survival rates in mice with brain, pancreatic, and lung cancers.
Zang’s innovative approach not only focuses on a more specific target but also incorporates a novel co-stimulator, TMIGD2, which enhances the activation and persistence of T-lymphocytes. The study demonstrates superior therapeutic efficiency compared to existing CAR-T therapies, offering hope for challenging solid tumors that have been resistant to current treatments.
A Bright Future Ahead
Zang’s research marks a significant stride in advancing CAR-T therapies for solid tumors, addressing the complexities of tumor microenvironments and enhancing targeting specificity. While the study is a crucial milestone, further clinical trials are needed to validate its efficacy in human patients. The potential of this new treatment signals a promising future in cancer therapy, with the possibility of overcoming previously resistant solid tumors.
Sign up for our weekly newsletter to receive more English-language news coverage from EL PAÍS USA Edition